Table 1. CircRNAs in leukemia.
| Leukemia types |
circRNA (circBase ID) |
Host gene | Expression | Source | miRNA sponge (target gene/pathway) | Functions | Clinical significance | Reference |
| AML | f-circPR, f-circM9_1 |
PML/RARα, MLL/AF9 | upregulated | BM | - | Facilitate cell transformation, vitality and resistance to treatment | Potential diagnostic and therapeutic implications | [44] |
| AML | circ-PVT1 (hsa_circ_0001821) |
PVT1 | upregulated | PB | let-7 or miR-125 families* | Involved in the development of leukemia | Help to explore biological mechanisms behind MYC amplifications | [46] |
| AML | circNPM1 75001 (hsa_circ_0075001) |
NPM1 | upregulated | BM | miR-181 family/ TLR signaling pathway* | Associated with myeloid differentiation | A potential biomarker for classification and risk stratification | [51] |
| AML | circ-HIPK2 (hsa_circ_0001756) |
HIPK2 | downregulated | PB | miR-124-3p | Regulate ATRA-induced differentiation | A potential biomarker | [52] |
| AML | circ-ANAPC7 (has_circ_101141) | ANAPC7 | upregulated | BM | miR-181 family* | Participate in the pathogenesis of AML | A promising diagnostic biomarker and novel drug target | [54] |
| AML | circRNA-DLEU2 (hsa_circ_0000488) |
DLEU2 | upregulated | BM | miR-496/PRKACB | Promote cell proliferation and inhibited cell apoptosis | A novel biomarker and therapeutic target | [55] |
| AML | hsa_circ_100290 | SLC30A7. | upregulated | BM | miR-203/Rab10 | Promote cell proliferation and inhibited cell apoptosis | A potential diagnostic and therapeutic target | [56] |
| AML | hsa_circ_0004277 | WDR37 | downregulated | BM | miR-138-5p, miR-30c-1-3p, miR-892b, miR-571, miR-328-3p/SH3GL2, PPARGC1A, PIP4K2C, SH2B3, ZNF275, and ATP1B4* | Associated with risk-status and treatment | A potential diagnostic biomarker | [62] |
| AML | circ_0009910 (hsa_circ_100053) |
MFN2 | upregulated | BM | miR-20a-5p. | Promote cell proliferation, cell cycle arrest and inhibit c629ell apoptosis | A novel outcome biomarker and potential therapeutic targets | [63] |
| AML | circ-PAN3 (hsa_circ_0100181) |
PAN3 | upregulated | BM | miR-153-5p/miR-183-5p/XIAP | Mediate the development of drug resistance | A valuable indicator for predicting clinical efficacy and potential target for reversing drug resistance | [64]. |
| ALL | circPVT1 | PVT1 | upregulated | BM | let-7, miR-125*/ Bcl-2, c-Myc | Promote cell proliferation inhibit cell apoptosis | A potential therapeutic target | [70] |
| CML | circBA9.3 | BCR-ABL1 | upregulated | PB | - | Promote cell proliferation, TKI resistance and inhibit apoptosis | A potential diagnostic and therapeutic target for TKI-resistant patients | [73] |
| CLL | circ-CBFB (hsa_circ_0000707) |
CBFB | upregulated | CLL cells | miR-607/FZD3/Wnt/β-catenin | Promote CLL cell proliferation, cell cycle progression and inhibit cellular apoptosis | An effective diagnostic and prognostic biomarker | [77] |
| CLL | circ_0132266 (hsa_circ_0132266) | MTO1 | downregulated | CLL cells | miR-337-3p/PML | Inhibit CLL cell proliferation, and promote apoptosis | An effective diagnostic and prognostic biomarker | [78] |
This table summarizes circRNAs that have been identified in human leukemia (AML, ALL, CML, CLL) and their roles in diagnosis, prognosis, disease progression, drug response evaluation. Information including host genes, expression levels, miRNA targets (direct and indirect), clinical values are shown (*Not validated experimentally; -Not mentioned).